Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 164Lung Neoplasms 61Small Cell Lung Carcinoma 24Neoplasms 10NSCLC 9Mesothelioma, Malignant 9Breast Neoplasms 8Pancreatic Neoplasms 7Ovarian Neoplasms 7Melanoma 6Head and Neck Neoplasms 6Colorectal Neoplasms 6Esophageal Neoplasms 5Stomach Neoplasms 4Neoplasm Metastasis 4Mesothelioma 4Kidney Neoplasms 4Brain Neoplasms 4Sarcoma 3Pleural Effusion, Malignant 3Liver Neoplasms 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3Carcinoma 3Adenocarcinoma of Lung 3Uterine Cervical Neoplasms 2Thymus Neoplasms 2Thymoma 2Small Cell Lung Cancer Limited Stage 2Skin Neoplasms 2

Interventions

Immunotherapy 2anlotinib 1Radiotherapy 1Drug Therapy 1Docetaxel 1Cisplatin 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Non-small Cell Lung Cancer × Drug Therapy × Thoracic × Clear all
NCT05481775 2022-11-21

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Withdrawn
Thoracic

Locally Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡